• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by RVL Pharmaceuticals plc

    11/20/23 8:47:44 AM ET
    $RVLP
    Pharmaceuticals and Biotechnology
    Health Care
    Get the next $RVLP alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 333-227357
    Issuer: RVL Pharmaceuticals plc
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 400 Crossing Boulevard
    Bridgewater NEW JERSEY 08807
    Telephone number: (908) 809-1314
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Ordinary Shares
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2023-11-20 By Aravind Menon Hearings Advisor
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RVLP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RVLP

    DatePrice TargetRatingAnalyst
    10/21/2022$2.50Hold
    Jefferies
    4/5/2022$4.00Overweight
    Barclays
    More analyst ratings

    $RVLP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies resumed coverage on RVL Pharmaceuticals with a new price target

      Jefferies resumed coverage of RVL Pharmaceuticals with a rating of Hold and set a new price target of $2.50

      10/21/22 7:38:37 AM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care
    • Barclays resumed coverage on RVL Pharmaceuticals with a new price target

      Barclays resumed coverage of RVL Pharmaceuticals with a rating of Overweight and set a new price target of $4.00

      4/5/22 7:57:14 AM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care

    $RVLP
    SEC Filings

    See more
    • RVL Pharmaceuticals plc filed SEC Form 8-K: Other Events

      8-K - RVL Pharmaceuticals plc (0001739426) (Filer)

      2/13/24 4:05:38 PM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care
    • RVL Pharmaceuticals plc filed SEC Form 8-K: Other Events

      8-K - RVL Pharmaceuticals plc (0001739426) (Filer)

      1/17/24 4:05:41 PM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care
    • RVL Pharmaceuticals plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - RVL Pharmaceuticals plc (0001739426) (Filer)

      12/20/23 4:15:51 PM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care

    $RVLP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • RVL Pharmaceuticals plc Announces Prepackaged Reorganization of Certain U.S. Subsidiaries

      Lender to Provide Incremental Liquidity to Support Long-Term Growth Senior Secured Lender to Exchange Outstanding Debt into Equity of the Reorganized Entities Business Operations at U.S. Subsidiaries to Continue as They Pursue Strategic Plan RVLP Ordinary Shares Expected to be Cancelled BRIDGEWATER, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc ("RVL" or "the Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or droopy eyelid, in adults, today announced that certain of its U.S. operating subsidiaries, RevitaLid Pharmaceutical C

      10/12/23 6:50:00 AM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care
    • RVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment Conference

      BRIDGEWATER, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company, today announced that Brian Markison, Chief Executive Officer, will participate in a fireside chat and host 1x1 investor meetings at the H.C. Wainwright 25th Annual Global Investment Conference in New York City as follows: Date:Tuesday, September 12, 2023  Time:11:30 am ET  Webcast:Click here To schedule a 1x1 investor meeting with the Company, please contact [email protected] at H.C. Wainwright. The live and archived webcast of the fireside chat will be accessible from the Company's website at www.rvlpharma.com, under the Investors & New

      8/23/23 4:05:00 PM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care
    • RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

      BRIDGEWATER, N.J., Aug. 16, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, today announced that it has entered into definitive agreements for the purchase and sale of 11,870,846 of its ordinary shares (or ordinary share equivalents in lieu thereof) at a purchase price of $0.4212 per ordinary share (or ordinary share equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. The Company also agreed

      8/16/23 8:00:00 AM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care

    $RVLP
    Financials

    Live finance-specific insights

    See more
    • RVL Pharmaceuticals plc Reports Second Quarter 2023 Financial Results; Provides Update on Strategic Business Review

      -- UPNEEQ® remains a significant potential value driver given its rapid early acceptance by providers, large total addressable market and untapped consumer opportunity -- -- Executed financing amendment with Athyrium, which, subject to certain conditions, would provide meaningful flexibility as part of our ongoing strategy to invest in UPNEEQ and drive growth -- -- The Company is in discussions with strategic targets that could accelerate UPNEEQ sales, broaden the Company's portfolio and leverage the field force investment -- -- Second quarter 2023 UPNEEQ net product sales of $8.3 million and operating expenses of $14.4 million, down 2% and 32%, respectively, compared to the prior year pe

      8/14/23 6:50:51 AM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care
    • RVL Pharmaceuticals plc to Discuss Second Quarter 2023 Financial Results and Provide Commercial Update

      BRIDGEWATER, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today announced that the Company will release its second quarter 2023 financial results and provide a commercial update on Monday, August 14, 2023, before U.S. financial markets open. Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Mike DePetris, Principal Accounting Officer, will host a conference call as follows: Date     Monday, August 14, 2023Time 8:30 a.m. ETRegister* (audio only) Click hereW

      8/2/23 8:30:00 AM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care
    • RVL Pharmaceuticals plc Reports First Quarter 2023 Financial Results; Provides Commercial Update

      -- First quarter 2023 UPNEEQ® net product sales grew 49%, or $2.9 million, over the prior year period to $8.8 million -- -- Enhanced operating leverage with a 32%, or $7.9 million, reduction in first quarter 2023 total operating expenditures from the prior year -- -- Majority of aesthetic orders in the first quarter, or 54%, represented reorder activity -- -- Approximately 4,800 cumulative unique medical aesthetics practices had placed orders for UPNEEQ through the end of the first quarter, a 12% increase from prior quarter end -- -- UPNEEQ Won "Best Eye Drop for Drooping Lids" NewBeauty in 13th Annual Beauty Awards, selected from among 10,000 entrants -- BRIDGEWATER, N.J., M

      5/11/23 6:50:55 AM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care

    $RVLP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by RVL Pharmaceuticals plc (Amendment)

      SC 13D/A - RVL Pharmaceuticals plc (0001739426) (Subject)

      11/27/23 9:24:25 PM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form SC 13D/A filed by RVL Pharmaceuticals plc (Amendment)

      SC 13D/A - RVL Pharmaceuticals plc (0001739426) (Subject)

      11/1/23 4:27:14 PM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form SC 13D/A filed by RVL Pharmaceuticals plc (Amendment)

      SC 13D/A - RVL Pharmaceuticals plc (0001739426) (Subject)

      10/13/23 5:28:49 PM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care

    $RVLP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Harsaul Foundation sold $580,147 worth of Ordinary Shares (14,122,659 units at $0.04) (SEC Form 4)

      4 - RVL Pharmaceuticals plc (0001739426) (Issuer)

      10/23/23 4:23:52 PM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care
    • Altchem Ltd sold $580,147 worth of Ordinary Shares (14,122,659 units at $0.04), decreasing direct ownership by 74% to 4,941,101 units (SEC Form 4)

      4 - RVL Pharmaceuticals plc (0001739426) (Issuer)

      10/23/23 1:06:00 PM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care
    • Harsaul Foundation sold $221,031 worth of Ordinary Shares (3,421,537 units at $0.06) (SEC Form 4)

      4 - RVL Pharmaceuticals plc (0001739426) (Issuer)

      10/20/23 3:59:45 PM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care